Novel Sources of Fetal Stem Cells for Future Regenerative Medicine

Yani Lina, Andi Wijaya

Abstract


BACKGROUND: Mesenchymal stromal cells are multipotent cells considered to be of great promise for use in regenerative medicine. However, the cell dose may be a critical factor in many clinical conditions and the yield resulting from the ex vivo expansion of mesenchymal stromal cells derived from bone marrow may be insufficient. Thus, alternative sources of mesenchymal stromal cells need to be explored.

CONTENT: There are multiple extra-embryonic tissues emerging during gestation including umbilical cord blood (UCB), amniotic fluid (AF), Wharton’s jelly, the amniotic membrane and the placenta, which are all discarded following birth. Fetal stem cells from these sources actually represent a new class of stem cells developmentally and operationally located between the state of embryonic stem cells and adult stem cells, sharing and exhibiting features of pluripotency and multipotency, without necessarily implying that they can generate every type of tissue.

SUMMARY: Fetal stem cells have been recently isolated from several tissues (amniotic fluid, umbilical cord, Wharton’s jelly, amnion and placenta). They are derived either from the fetus proper or from the supportive extra-embryonic structures. They represent ideal sources for regenerative medicine since they are easily accessible, exhibit high proliferation rates, do not form teratomas and present no ethical reservations like embryonic stem cells (ESC). Their functional features indicate that they actually represent intermediates between ESC and adult stem cells.

KEYWORDS: mesenchymal stem cells, fetal stem cells, amniotic fluid, umbilical cord, placenta, wharton’s jelly


Full Text:

PDF

References


Williams AR, Hare JM. Mesenchymal stem cells: Biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res. 2011; 109: 923-40, CrossRef.

Friedenstein AJ, Chailakhjan RK, Lalykina KS. The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. Cell Tissue Kinet. 1970; 3: 393-403, CrossRef.

Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hematopoietic tissues: Cloning in vitro and retransplantation in vivo. Transplantation. 1974; 17: 331-40, CrossRef.

Piersma AH, Brockbank KG, Ploemacher RE, van Vliet E, Brakel-van Peer KM, Visser PJ. Characterization of fibroblastic stromal cells from murine bone marrow. Exp Hematol. 1985; 13: 237-43, PMID.

Caplan AI. Molecular and cellular differentiation of muscle, cartilage, and bone in the developing limb. Prog Clin Biol Res. 1986; 217B: 307-18, PMID.

Caplan AI. Mesenchymal stem cells. J Orthop Res. 1991; 9: 641-50, CrossRef.

Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brain. Proc Natl Acad Sci USA. 1999; 96: 10711-6, CrossRef.

Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, et al. Human bone marrow stromal cells supress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood. 2002; 99: 3838-43, CrossRef.

Waterman RS, Tomchuck SL, Henkie SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: Polarization into a proinflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS ONE. 2010; 5: e10088, CrossRef.

Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSC): Controversies, myths, and changing paradigms. Mol Ther. 2009; 17: 939-46, CrossRef.

Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell response. Blood. 2005; 105: 1815-22, CrossRef.

Ryan JM, Barry FP, Murphy JM, Mahon BP. Mesenchymal stem cells avoid allogeneic rejection. J Inflamm (Lond). 2005; 2: 8, PMID.

Nakahara H, Dennis JE, Bruder SP, Haynesworth SE, Lennon DP, Caplan AI. In vitro differentiation of bone and hypertrophic cartilage from periosteal-derived cells. Exp Cell Res. 1991; 195: 492-503, CrossRef.

Zuk PA, Zhu M, Mizuno H, De Ugarte DA, Huang JI, Mizuno H, et al. Multilineage cells from human adipose tissue: Implications for cell-based therapies. Tissue Eng. 2001; 7: 211-28, CrossRef.

Jankowski RJ, Deasy BM Huard J. Muscle derived stem cells. Gene Therapy. 2002; 9: 642-7, CrossRef.

Young HE, Steele TA, Bray RA, Hudson J, Floyd JA, Hawkins K, et al. Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult and geriatric donors. Anat Rec. 2001; 264: 51-62, CrossRef.

D'Ippolito G, Schiller PC, Ricordi C, Roos BA, Howard GA. Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J Bone Miner Res. 1999; 14: 1115-22, CrossRef.

Pappa KI, Anagnou NP. Novel sources of fetal stem cells: Where do they fit on the developmental continuum ? Regen Med. 2009; 4: 423-33, CrossRef.

Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999; 284: 143-7, CrossRef.

Zuk PA, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002; 13: 4279-95, CrossRef.

Xu Y, Malladi P, Wagner DR, Longaker MT. Adipose-derived mesenchymal cells as a potential cell source for skeletal regeneration. Curr Opin Mol Ther. 2005; 7: 300-5, PMID.

Bieback K, Kern S, Klüter H, Eichler H. Critical parameters for the isolation of mesenchymal stem cells from umbilical cord blood. Stem Cells. 2004; 22: 625-34, CrossRef.

Tsai MS, Lee JL, Chang YJ, Hwang SM. Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum Reprod. 2004; 19: 1450-6, CrossRef.

Tsai MS, Hwang SM, Tsai YL, Cheng FC, Lee JL, Chang YJ. Clonal amniotic fluid-derived stem cells express characteristics of both mesenchymal and neural stem cells. Biol Reprod. 2006; 74: 545-51, CrossRef.

Zhao P, Ise H, Hongo M, Ota M, Konishi I, Nikaido T. Human amniotic mesenchymal cells have some characteristics of cardiomyocytes. Transplantation. 2005; 79: 528-35, CrossRef.

Ochsenbein-Kölble N, Bilic G, Hall H, Huch R, Zimmermann R. Inducing proliferation of human amnion epithelial and mesenchymal cells for prospective engineering of membrane repair. J Perinat Med. 2003; 31: 287-94, PMID.

In't Anker PS, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, et al. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells. 2004; 22: 1338-45, CrossRef.

Portmann-Lanz CB, Schoeberlein A, Huber A, Sager R, Malek A, Holzgreve W. Placental mesenchymal stem cells as potential autologous graft for pre- and perinatal neurogeneration. Am J Obstet Gynecol. 2006; 194: 664-73, CrossRef.

Kim JW, Kim SY, Park SY, Kim YM, Kim JM, Lee MH, et al. Mesenchymal progenitor cells in the human umbilical cord. Ann Hematol. 2004; 83: 733-8, CrossRef.

Fu YS, Cheng YC, Lin MY, Cheng H, Chu PM, Chou SC, et al. Conversion of human umbilical cord mesenchymal stem cells in wharton’s jelly to dopaminergic neurons in vitro: Potential therapeutic application for parkinsonism. Stem Cells. 2006; 24: 115-24, CrossRef.

Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, et al. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999; 5: 309-13, PMID.

Koc ON, Gerson SL, Cooper BW, Dyhouse SM, Haynesworth SE, Caplan AL, et al. Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol. 2000; 18: 307-16, PMID.

Mueller SM, Glowacki J. Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J Cell Biochem. 2001; 82: 583-90, CrossRef.

Gimble JM, Guilak F. Differentiation potential of adipose derived adult stem cell (ADAS) cells. Curr Top Dev Biol. 2003; 58: 137-60, CrossRef.

Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol. 2005; 33: 1402-16, CrossRef.

Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006; 24: 1294-301, CrossRef.

Halvorsen YD, Franklin D, Bond AL, Hitt DC, Auchter C, Boskey AL, et al. Extracellular matrix mineralization and osteoblast gene expression by human adipose tissue-derived stromal cells. Tissue Eng. 2001; 7: 729-41, CrossRef.

Mizuno H, Zuk PA, Zhu M, Lorenz HP, Benhaim P, Hedrick MH. Myogenic differentiation by human processed lipoaspirate cells. Plast Reconstr Surg. 2002; 109: 199-209, CrossRef.

Safford KM, Hicok KC, Safford SD, Halvorsen Y-DC, Wilkinson WO, Gimble JM, et al. Neurogenic differentiation of murine and human adipose-derived stromal cells. Biochem Biophys Res Commun. 2002; 294: 371-9, CrossRef.

Izadpanah R, Trygg C, Patel B, Kriedt C, Dufour J, Gimble JM, et al. Biologic properties of mesenchymal stem cells derived from bone marrow and adipose tissue. J Cell Biochem. 2006; 99: 1285-97, CrossRef.

Sessarego N, Parodi A, Podesta M, Benvenuto F, Mogni M, Raviolo V, et al. Multipotent mesenchymal stromal cells from amniotic fluid: Solid perspectives for clinical application. Haematologica. 2008; 93: 339-46, CrossRef.

Reinisch A, Bartmann C, Rohde E, Schallmoser K, Bjelic-Radisic V, Lanzer G, et al. Humanized system to propagate cord blood-derived multipotent mesenchymal stromal cells for clinical application. Regen Med. 2007; 2: 371-82, CrossRef.

Kita K, Gauglitz GG, Phan TT, Herndon DN, Jeschke MG. Isolation and characterization of mesenchymal stem cells from the sub-amniotic human umbilical cord lining membrane. Stem Cells Dev. 2010; 19: 491-501, CrossRef.

Parolini O, Alviano F, Bagnara GP, Bilic G, Buhring HJ, Evangelista M, et al. Concise review: Isolation and characterization of cells from human term placenta: Outcome of the first international workshop on placenta derived stem cells. Stem Cells. 2008; 26: 300-11, CrossRef.

Karahuseyinoglu S, Cinar O, Kilic E, F Kara, GG Akay, DO Demiralp, et al. Biology of the stem cells in human umbilical cord stroma: In situ and in vitro surveys. Stem Cells. 2007; 25: 319-31, CrossRef.

Romanov YA, SvintsitskayaVA, Smirnov VN. Searching for alternative sources of postnatal human mesenchymal stem cells: Candidate MSC-like cells from umbilical cord. Stem Cells. 2003; 21: 105-10, CrossRef.

Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al. Mesenchymal stem cells in the wharton’s jelly of the human umbilical cord. Stem Cells. 2004; 22: 1330-7, CrossRef.

Sarugaser R, Lickorish D, Baksh D, Hosseini MM, Davies JE. Human umbilical cord perivascular (HUCPV) cells: A source of mesenchymal progenitors. Stem Cells. 2005; 23: 220-9, CrossRef.

Can A, Karahuseyinoglu S. Concise review: Human umbilical cord stroma with regards to the source of fetus-derived stem cells. Stem Cells. 2007; 25: 2886-95, CrossRef.

Hemberger M, Yang W, Natale D, Brown TL, Dunk C, Gargett CE, et al. Stem cells from fetal membranes: A workshop report. Placenta. 2008; 29 Suppl A: S17-9, CrossRef.

DeCoppi P, Bartsch G Jr, Siddiqui MM, Xu T, Santos CC, Perin L, et al. Isolation of amniotic stem cells with potential for therapy. Nat Biotechol. 2007; 25: 100-6, CrossRef.

Roubelakis MG, Pappa KI, Bitsika V, Zagoura D, Vlahou A, Papadaki HA, et al. Molecular and proteomic characterization of human mesenchymal stem cells derived from amniotic fluid: Comparison to bone marrow mesenchymal stem cells. Stem Cells Dev. 2007; 16: 931-52, CrossRef.

Kim J, Lee Y, Kim H, Hwang KJ, Kwon HC, Kim SK, et al. Human amniotic fluid-derived stem cells have characteristics of multipotent stem cells. Cell Prolif. 2007; 40: 75-90, CrossRef.

Bossolasco P, Montemurro T, Cova L, Zangrossi S, Calzarossa C, Buiatiotis S, et al. Molecular and phenotypic characterization of human amniotic fluid cells and their differentiation potential. Cell Res. 2006; 16: 329-36, CrossRef.

Prusa AR, Morton E, Rosner M, Bernaschek G, Hengstschlager M. Oct-4 expressing cells in human amniotic fluid: A new source for stem cell research ? Hum Reprod. 2003; 18: 1489-93, CrossRef.

Prusa AR, Marton E, Rosner M, et al. Neurogenic cells in human amniotic fluid. Am J Obstet Gynecol. 2004; 191: 309-14, CrossRef.

Perin L, Sedrakyan S, Da Sacco S, De Filippo R. Characterization of human amniotic fluid stem cells and their pluripotential capacity. Methods Cell Biol. 2008; 86: 85-99, CrossRef.

Kolambkar YM, Peister A, Soker S, Atala A, Guldberg RE. Chondrogenic differentiation of amniotic fluid-deriven stem cells. J Mol Histol. 2007; 38: 405-13, CrossRef.

Kunisaki SM, Armant M, Kao GS, Stevenson K, Kim H, Fauza DO. Tissue engineering from human mesenchymal amniocytes: A prelude to clinical trials. J Pediatr Surg. 2007; 42: 974-80, CrossRef.

Hoehn H, Salk D. Morphological and biochemical heterogeneity of amniotic fluid cells in culture. In: Latt SA, Darlington GJ, editors. Methods in Cell Biology Volume 26. Philadeplhia: Elseveier; 1982. 11-34, CrossRef.

Heidari Z, Isobe K, Goto S, Nakashima I, Kiuchi K, Tomoda Y. Characterization of the growth factor activity of amniotic fluid on cells from hematopoietic and lymphoid organs of different life stages. Microbiol Immunol. 1996; 40: 583-9, CrossRef.

Srivastava MD, Lippes J, Srivastava BI. Cytokines of the human reproductive tract. Am J Reprod Immunol.1996; 36: 157-66, CrossRef.

Bartha JL, Romero-Carmona R, Comino-Delgado R, Arce F, Arrabal J. Alpha-fetoprotein and hematopoietic growth factors in amniotic fluid. Obstet Gynecol. 2000; 96: 588-92, CrossRef.

Bili C, Divane A, Apessos A, Konstantinos T, Apostolos A, Ioannis B, et al. Prenatal diagnosis of common aneuploidies using quantitative fluorescent PCR. Prenat Diagn. 2002; 22: 360-5, CrossRef.

Meron PM. Preparation, culture and analysis of amniotic fluid samples. Curr Protoc Hum Genet. 2001; Chapter 8: Unit 8.4, CrossRef.

Kaviani A, Perry TE, Dzakovic A, Jennings RW, Ziegler MM, Fauza DO. The amniotic fluid as a source of cells for fetal tissue engineering. J Pediatr Surg. 2001; 36: 1662-5, CrossRef.

Kaviani A, Guleserian K, Perry TE, Jennings RW, Ziegler MM, Fauza DO. Fetal tissue engineering from amniotic fluid. J Am Coll Surg. 2003; 196: 592-7, CrossRef.

In’t Anker PS, Scherjon SA, Kleijburg–van der Keur C, Noort WA, Claas FH, Willemze R, et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood. 2003; 102: 1548-9, CrossRef.

Fehrer C, Lepperdinger G. Mesenchymal stem cell aging. Exp Gerontol. 2005; 40: 926-30, CrossRef.

Sethe S, Scutt A, Stolzing A. Aging of mesenchymal stem cells. Ageing Res Rev. 2006; 5: 91-116, CrossRef.

Wagner W, Horn P, Castoldi M, Diehlmann A, Bork S, Saffrich R, et al. Replicative senescence of mesenchymal stem cells: A continuous and organized process. PLoS One. 2008; 3: e2213, CrossRef.

Kim J, Kang JW, Park JH, Choi Y, Choi KS, Park KD, et al. Biological characterization of long-term cultured human mesenchymal stem cells. Arch Pharm Res. 2009; 32: 117-26, CrossRef.

Chen WQ, Siegel N, Li L, Pollak A, Hengstschlager M, Lubec G. Variations of protein levels in human amniotic fluid stem cells CD117/2 over passages 5-25. J Proteome Res. 2009; 8: 5285-95, CrossRef.

Miranda-Sayago JM, Fernandez-Arcas N, Benito C, Reyes-Engel A, Carrera J, Alonso A. Lifespan of human amniotic fluid-derived multipotent mesenchymal stromal cells. Cytotherapy. 2011; 13: 572-81, CrossRef.

Bollini S, Cheung KK, Riegler J, Dong X, Smart N, Ghionzoli M, et al. Amniotic fluid stem cells are cardioprotective following acute myocardial infarction. Stem Cells Dev. 2011; 20: 1985-94, CrossRef.

Bitsika V, Roubelakis MG, Zagoura , Trohatou O, Makridakis M, Pappa KI, et al. Human amniotic fluid-derived mesenchymal stem cells as therapeutic vehicles: A novel approach for the treatment of bladder cancer. Stem Cells Dev. 2012; 21: 1097-111, CrossRef.

Broxmeyer HE, Srour E, Orschell C, Ingram DA, Cooper S, Plett PA, et al. Cord blood stem cells and progenitor cells. Methods Enzymol. 2006; 419: 439-73, CrossRef.

Tondreau T, Meuleman N, Delforge A, Dejeneffe M, Leroy R, Massy M, et al. Mesenchymal stem cells derived from CD133-positive cells in mobilized peripheral blood and cord blood: Proliferation, Oct-4 expression and plasticity. Stem Cells. 2005; 23: 1105-12, CrossRef.

Greco SJ, Lin K, Rameshwar P. Functional similarities among genes regulated by Oct4 in human mesenchymal and embryonic stem cells. Stem Cells. 2007; 25: 3143-54, CrossRef.

McGuckin CP, Forraz N, Baradez MO, Navran S, Zhao J, Urban R, et al. Production of stem cells with embryonic characteristics from human umbilical cord blood. Cell Prolif. 2005; 38: 245-55, CrossRef.

Zhao Y, Wang H, Mazzone T. Identification of stem cells from human umbilical cord blood with embryonic and hematopoietic characteristics. Exp Cell Res. 2006; 312: 2454-64, CrossRef.

Markov V, Kusumi K, Tadesse MG, William DA, Hall DM, Lounev V, et al. Identification of cord blood-derived mesenchymal stem/stromal cell populations with distinct growth kinetics, differentiation potentials, and gene expression profiles. Stem Cells Dev. 2007; 16: 53-74, CrossRef.

Sun B, Roh KH, Lee SR, Lee YS, Kang KS. Induction of human umbilical cord blood-derived stem cells with embryonic stem cell phenotypes into insulin producing islet-like structures. Biochem Biophys Res Commun. 2007; 354: 919-23, CrossRef.

Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood. 2004; 103: 1669-75, CrossRef.

Madlambayan G, Rogers I. Umbilical cord-derived stem cells for tissue therapy: Current and future uses. Regen Med. 2006; 1: 777-87, CrossRef.

Meyer FA, Laver-Rudich Z, Tanenbaum R. Evidence for a mechanical coupling of glycoprotein in microfibrils with collagen fibrils in wharton’s jelly. Biochim Biophys Acta. 1983; 755: 376-87, CrossRef.

Sobolewski K, Bańkowski E, Chyczewski L, Jaworski S. Collagen and glycosaminoglycans of wharton’s jelly. Biol Neonate. 1997; 71: 11-21, CrossRef.

Sakamoto T, Ono H, Saito Y. Electron microscope histochemical studies on the location of hyaluronic acid in wharton’s jelly of the human umbilical cord. Nippon Sanka Fujinka Gakkai Zasshi. 1996; 48: 501-7.

Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YJ, et al. Mesenchymal stem cells in the wharton’s jelly of the human umbilical cord. Stem Cells. 2004; 22: 1330-7, CrossRef.

Pereira WC, Khushnooma I, Madkaikar M, Ghosh K. Reproducible methodology for the isolation of mesenchymal stem cells from human umbilical cord and its potential for cardiomyocyte generation. J Tissue Eng Regen Med. 2008; 2: 394-9, CrossRef.

Lu LL, Liu YJ, Yang SG, Zhao QJ, Wang X, Gong W, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica. 2006; 91: 1017-26, PMID.

Kadam SS, Tiwari S, Bhonde RR. Simultaneous isolation of vascular endothelial cells and mesenchymal stem cells from the human umbilical cord. In Vitro Cell Dev Biol Anim. 2009; 45: 23-7, CrossRef.

Nekanti U, Rao VB, Bahirvani AG, Jan M, Totey S, Ta M. Long-term expansion and pluripotent marker array analysis of wharton’s jelly-derived mesenchymal stem cells. Stem Cells Dev. 2010; 19: 117-30, CrossRef.

De Bruyn C, Najar M, Raicevic G, Meuleman N, Pieters K, Stamapoulos B, et al. A rapid, simple, and reproducible method for the isolation of mesenchymal stromal cells from wharton’s jelly without enzymatic treatment. Stem Cells Dev. 2011; 20: 547-57, CrossRef.

Troyer DL, Weiss ML. Concise review: Wharton’s jelly-derived cells are a primitive stromal cell population. Stem Cells. 2008; 26: 591-9, CrossRef.

Conconi MT, Burra P, Di Liddo R, Calore C, Turetta M, Bellini S, et al. CD105+ cells from wharton’s jelly show in vitro and in vivo myogenic differentiation potential. Int J Mol Med. 2006; 18: 1089-96, CrossRef.

Mitchell KE, Weiss ML, Mitchell BM, Martin P, Davis D, Morales L, et al. Matrix cells from wharton’s jelly form neurons and glia. Stem Cells. 2003; 21: 50-60, CrossRef.

Kadner A, Hoerstrup SP, Tracy J, Breymann C, Maurus CF, Melnitchouk S, et al. Human umbilical cord cells: A new cell source for cardiovascular tissue engineering. Ann Thorac Surg. 2002; 74: S1422-8, CrossRef.

Anzalone R, Lo Iacono M, Corrao S, Magno F, Loria T, Cappello F, et al. New emerging potentials for human wharton’s jelly mesenchymal stem cells: Immunological features and hepatocyte-like differentiative capacity. Stem Cells Dev. 2010; 19: 423-38, CrossRef.

Fan CG, Zhang Q, Zhou JR. Therapeutic potentials of mesenchymal stem cells derived from human umbilical cord. Stem Cell Rev. 2011; 7: 195-207, CrossRef.

Chao KC, Chao KF, Fu YS, Liu SH. Islet-like clusters derived from mesenchymal stem cells in wharton’s jelly of the human umbilical cord for transplantation to control type I diabetes. PLoS ONE. 2008; 3: e1451, CrossRef.

Bailey MM, Wang L, Bode CJ, Mitchell KE, Detamore MS. A comparison of human umbilical cord matrix stem cells and temporomandibular joint condylar chondrocytes for tissue engineering temporomandibular joint condylar cartilage. Tissue Eng. 2007; 13: 2003-10, CrossRef.

Baksh D, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. Stem Cells. 2007; 25: 1384-92, CrossRef.

Naughton BA. Cells isolated from wharton’s jelly of the human umbilical cord develop a cartilage phenotype when treated with TGF-β in vitro. FASEB J. 1997; 11: A19.

Wang L, Ott L, Seshareddy K, Weiss ML, Detamore MS. Musculoskeletal tissue engineering with human umbilical cord mesenchymal stromal cells. Regen Med. 2011; 6: 95-109, CrossRef.

Fu YS, Shih YT, Cheng YC, Min MY. Transformation of human umbilical mesenchymal cells into neurons in vitro. J Biomed Sci. 2004; 11: 652-60, CrossRef.

Fu YS, Cheng YC, Lin MY, Cheng H, Chu PM, Chou SC, et al. Conversion of human umbilical cord matrix stem cells in wharton’s jelly to dopaminergic neurons in vitro: Potential therapeutic application for parkinsonism. Stem Cells. 2006; 24: 115-24, CrossRef.

Lin YC, Ko TL, Shih YH, Anya Lin MY, Fu TW, Hsiao HS, et al. Human umbilical mesenchymal stem cells promote recovery after ischemic stroke. Stroke. 2011; 42: 2045-53, CrossRef.

Tsuji H, Miyoshi S, Ikegami Y, Hida N, Asada H, Togashi I, et al. Xenografted human amniotic membrane-derived mesenchymal stem cells are immunologically tolerated and transdifferentiated into cardiomyocytes. Circ Res. 2010; 106: 1613-23, CrossRef.

Marcus AJ, Coyne TM, Rauch J, Woodburry D, Black IB. Isolation, characterization and differentiation of stem cells derived from the rat amniotic membrane. Differentiation. 2008; 76: 130-44, CrossRef.

Alviano F, Fossati V, Marchionni C, Arpinati M, Bonsi L, Franchina M, et al. Term amniotic membrane is a high throughput source for multipotent mesenchymal stem cells with the ability to differentiate into endothelial cells in vitro. BMC Dev Biol. 2007; 7: 11, CrossRef.

Parolini O, Alviano F, Bergwerf I, Boraschi D, De Bari C, De Waele P, et al. Toward cell therapy using placenta-derived cells: Disease mechanisms, cell biology, preclinical studies, and regulatory aspects at the round table. Stem Cells Dev. 2010; 19: 143-54, CrossRef.

Miki T, Lehmann T, Cai H, Stolz DB, Strom SC. Stem cell characteristics of amniotic epithelial cells. Stem Cells. 2005; 23: 1549-59, CrossRef.

Sakuragawa N, Misawa H, Ohsugi K, Kakishita K, Ishii T, Thangavel R, et al. Evidence for active acetylcholine metabolism in human amniotic epithelial cells: Applicable to intracerebral allografting for neurologic disease. Neurosci Lett. 1997; 232: 53-6, CrossRef.

Elwan MA, Sakuragawa N. Evidence for synthesis and release of catecholamin by human amniotic epithelial cells. Neuroreport. 1997; 8: 3435-8, CrossRef.

Sakuragawa N, Thangavel R, Mizuguchi M, Hirasawa M, Kamo I. Expression of markers for both neuronal and glial cells in human amniotic epithelial cells. Neurosci Lett. 1996; 209: 9-12, CrossRef.

Kakishita K, Elwan MA, Nakao N, Itakura T, Sakuragawa N. Human amniotic epithelial cells produce dopamine and survive after implantation into the striatum of a rat model of parkinson's disease: a potential source of donor for transplantation therapy. Exp Neurol. 2000; 165: 27-34, CrossRef.

Kakishita K, Nakao N, Sakuragawa N, Itakura T. Implantation of human amniotic epithelial cells prevents the degeneration of nigral dopamine neurons in rats with 6-hydroxydopamine lesions. Brain Res. 2003; 980: 48-56, CrossRef.

Bankiewicz KS, Palmatier M, Plunkett RJ, Cummins A, Oldfield EH. Reversal of hemiparkinsonian syndrome in nonhuman primates by amnion implantation into caudate nucleus. J Neurosurg. 1994; 81: 869-76, CrossRef.

Okawa H, Okuda O, Arai H, Sakuragawa N, Sato K. Amniotic epithelial cells transform into neuron-like cells in the ischemic brain. Neuroreport. 2001; 12: 4003-7, CrossRef.

Sankar V, Muthusamy R. Role of human amniotic epithelial cell transplantation in spinal cord injury repair research. Neuroscience. 2003; 118: 11-7, CrossRef.

Daley GQ, Hyun I, Lindvall O. Mapping the road to the clinical translation of stem cells. Cell Stem Cell. 2008; 2: 139-140, CrossRef.




DOI: https://doi.org/10.18585/inabj.v4i1.155

Indexed by:

                 

                  

               

     

 

The Prodia Education and Research Institute